STING1 and breast neoplasm: Consistent with the fact that STING activation upregulates PD-L1 expression in tumour cells35, we observed PD-L1 upregulation in 4T1 breast tumours following Vadimezan treatment (Supplementary Fig. 17), providing the rationale for combining Vadimezan with ICB.